Drug transporters in drug efficacy and toxicity.

Drug transporters are now widely acknowledged as important determinants governing drug absorption, excretion, and, in many cases, extent of drug entry into target organs. There is also a greater appreciation that altered drug transporter function, whether due to genetic polymorphisms, drug-drug interactions, or environmental factors such as dietary constituents, can result in unexpected toxicity. Such effects are in part due to the interplay between various uptake and efflux transporters with overlapping functional capabilities that can manifest as marked interindividual variability in drug disposition in vivo. Here we review transporters of the solute carrier (SLC) and ATP-binding cassette (ABC) superfamilies considered to be of major importance in drug therapy and outline how understanding the expression, function, and genetic variation in such drug transporters will result in better strategies for optimal drug design and tissue targeting as well as reduce the risk for drug-drug interactions and adverse drug responses.

[1]  K. Giacomini,et al.  Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.

[2]  Stephen G. Aller Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2010 .

[3]  Hyunyoung Jeong,et al.  Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. , 2010, Drug metabolism letters.

[4]  H. Potschka Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies? , 2010, Epilepsia.

[5]  R. Kaiser,et al.  Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron , 2010, The Pharmacogenomics Journal.

[6]  P. Neuvonen,et al.  Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. , 2011, British journal of clinical pharmacology.

[7]  Yuichi Sugiyama,et al.  Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.

[8]  B. Tomlinson,et al.  Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients , 2010, Pharmacogenetics and genomics.

[9]  A. Schinkel,et al.  Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.

[10]  A. Hofman,et al.  Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus , 2009, The Pharmacogenomics Journal.

[11]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[12]  Matthijs L. Becker,et al.  Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study , 2009, Diabetes.

[13]  A. S. Gross,et al.  Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. , 2010, Journal of pharmaceutical sciences.

[14]  M. Namer,et al.  CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN , 1986, The Lancet.

[15]  D. Keppler,et al.  The apical conjugate efflux pump ABCC2 (MRP2) , 2007, Pflügers Archiv - European Journal of Physiology.

[16]  S. Tsunoda,et al.  ABCG2 Expression Is an Independent Unfavorable Prognostic Factor in Esophageal Squamous Cell Carcinoma , 2007, Oncology.

[17]  Samy I McFarlane,et al.  Metformin: An Update , 2002, Annals of Internal Medicine.

[18]  H. Takane,et al.  Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin , 2006, Journal of Human Genetics.

[19]  B. Tomlinson,et al.  ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.

[20]  P. Kwok,et al.  Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1 , 2009, Pharmacogenetics and genomics.

[21]  E. van de Steeg,et al.  High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel , 2010, Clinical Cancer Research.

[22]  Andreas Rolfs,et al.  The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.

[23]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.

[24]  E. Burchard,et al.  Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin , 2009, Pharmacogenetics and genomics.

[25]  H. Koepsell,et al.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. , 2010, The American journal of pathology.

[26]  G. Burckhardt,et al.  In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. , 2011, Handbook of experimental pharmacology.

[27]  H. McLeod,et al.  Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.

[28]  H. Kusuhara,et al.  Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.

[29]  A. Fujimura,et al.  Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: First case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 , 2006, Clinical pharmacology and therapeutics.

[30]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[31]  R. Franke,et al.  Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.

[32]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[33]  M. McCarthy,et al.  Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study , 2009, Diabetes.

[34]  R. Callaghan,et al.  How can we best use structural information on P-glycoprotein to design inhibitors? , 2007, Pharmacology & therapeutics.

[35]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[36]  R. Kim,et al.  Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. , 2010, American journal of physiology. Renal physiology.

[37]  O. van Tellingen,et al.  Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo , 2009, Molecular Cancer Therapeutics.

[38]  J. Schellens,et al.  The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.

[39]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[40]  T. Miyawaki,et al.  Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. , 2011, Drug metabolism and pharmacokinetics.

[41]  H. Kusuhara,et al.  Prediction of Fluoroquinolone‐Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion , 2011, Clinical pharmacology and therapeutics.

[42]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[43]  C. Beglinger,et al.  Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. , 2005, Biochemical pharmacology.

[44]  T. Ishikawa,et al.  Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. , 2009, Journal of experimental therapeutics & oncology.

[45]  O. Ogawa,et al.  Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney , 2008, Journal of Human Genetics.

[46]  Swati S. More,et al.  Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice , 2010, Pharmaceutical Research.

[47]  M. Gionfriddo,et al.  Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. , 2009, Biopharmaceutics & drug disposition.

[48]  H. Endou,et al.  Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. , 2010, Journal of pharmacological sciences.

[49]  A. Wolff,et al.  Pharmacogenetic Pathway Analysis of Docetaxel Elimination , 2009, Clinical pharmacology and therapeutics.

[50]  Rachel M. Bailey,et al.  Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. , 2007, American journal of physiology. Renal physiology.

[51]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[52]  I. Roots,et al.  Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[53]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[54]  T. Mizuno,et al.  Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.

[55]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[56]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[58]  D. Oh,et al.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.

[59]  TP Hughes,et al.  OCT‐1 as a Determinant of Response to Antileukemic Treatment , 2011, Clinical pharmacology and therapeutics.

[60]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[61]  K. Park,et al.  Rifampin Enhances the Glucose‐Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants , 2011, Clinical pharmacology and therapeutics.

[62]  H. Koepsell,et al.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.

[63]  Liang-Shang Gan,et al.  Breast cancer resistance protein in pharmacokinetics and drug–drug interactions , 2005, Expert opinion on drug metabolism & toxicology.

[64]  U. Hofmann,et al.  Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid‐lowering efficacy of multiple‐dose pravastatin , 2006, Clinical pharmacology and therapeutics.

[65]  U. Pagotto,et al.  Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[66]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[67]  D. Steinbach,et al.  BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.

[68]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[69]  P. Kwok,et al.  Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function , 2009, The Pharmacogenomics Journal.

[70]  H. Endou,et al.  Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters , 2002, Journal of Pharmacology and Experimental Therapeutics.

[71]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[72]  A. Sparreboom,et al.  Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.

[73]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[74]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[75]  H. Kusuhara,et al.  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.

[76]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[77]  J. Lima,et al.  Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response , 2009, Pharmacogenetics and genomics.

[78]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[79]  Jae-Gook Shin,et al.  The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 , 2008, Pharmacogenetics and genomics.

[80]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.

[81]  M. Washington,et al.  Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. , 2008, Cancer research.

[82]  Joe Palandra,et al.  Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.

[83]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[84]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[85]  I Meineke,et al.  The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin , 2009, Clinical pharmacology and therapeutics.

[86]  Jos H Beijnen,et al.  Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.

[87]  J. Ware,et al.  Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.

[88]  K. Inui,et al.  Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[89]  H. Kusuhara,et al.  Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Res , 2009, Drug Metabolism and Disposition.

[90]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[91]  Conrad C. Huang,et al.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. , 2002, Pharmacogenetics.

[92]  A. Sparreboom,et al.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.

[93]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[94]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[95]  I. Song,et al.  Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. , 2008, Drug metabolism and pharmacokinetics.

[96]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[97]  Ya-li Liu,et al.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[98]  Cheng Cheng,et al.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[100]  Xingrong Liu,et al.  Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. , 2003, Current drug metabolism.

[101]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[102]  H. Rosing,et al.  P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration , 2011, Journal of Pharmacology and Experimental Therapeutics.

[103]  S. Cole,et al.  Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. , 2009, Biochemical and biophysical research communications.

[104]  D. Ross,et al.  Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.

[105]  S. Khoo,et al.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.

[106]  Soma Das,et al.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  J. Shin,et al.  Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.

[108]  Ting-ting Li,et al.  Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers , 2011, European Journal of Clinical Pharmacology.

[109]  J. Lima,et al.  Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast , 2011, Journal of clinical pharmacology.

[110]  T. Cihlar,et al.  Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.

[111]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[112]  K. Maeda,et al.  Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.

[113]  T. Doi,et al.  Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity , 2009, Journal of Human Genetics.

[114]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[115]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[116]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[117]  O. van Tellingen,et al.  Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo , 2009, Clinical Cancer Research.

[118]  H. Glaeser Importance of P-glycoprotein for drug-drug interactions. , 2011, Handbook of experimental pharmacology.

[119]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[120]  Supratim Choudhuri,et al.  Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[121]  H. Koepsell,et al.  Organic cation transporters in intestine, kidney, liver, and brain. , 1998, Annual review of physiology.

[122]  K. Mizuguchi,et al.  Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity , 2011, Pharmacogenetics and genomics.

[123]  E. Lopez-Lopez,et al.  Polymorphisms of the SLCO1B1 gene predict methotrexate‐related toxicity in childhood acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[124]  H. Kusuhara,et al.  P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION , 2005, Drug Metabolism and Disposition.

[125]  V. Vallon,et al.  Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. , 2008, American journal of physiology. Renal physiology.

[126]  F. Sharom ABC multidrug transporters: structure, function and role in chemoresistance. , 2008, Pharmacogenomics.

[127]  Rosalinde Masereeuw,et al.  Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. , 2008, Trends in pharmacological sciences.

[128]  Bradley L Urquhart,et al.  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.

[129]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[130]  U. Brinkmann,et al.  Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. , 2002, Pharmacogenetics.

[131]  M. Relling,et al.  Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. , 2008, Cancer Research.

[132]  坂田 武 Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions , 2004 .

[133]  P. Manley,et al.  Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[135]  T. Lumley,et al.  Cerivastatin, genetic variants, and the risk of rhabdomyolysis , 2011, Pharmacogenetics and genomics.

[136]  K. Maeda,et al.  SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[137]  K. Giacomini,et al.  Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions , 2011, The Pharmacogenomics Journal.

[138]  Hyeong-Seok Lim,et al.  Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. , 2008, Lung cancer.

[139]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[140]  I. Cascorbi P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. , 2011, Handbook of experimental pharmacology.

[141]  A. Schlessinger,et al.  Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function , 2010, Journal of Pharmacology and Experimental Therapeutics.

[142]  S. Masuda,et al.  Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. , 2010, Pharmacogenetics and genomics.

[143]  R. Kim,et al.  Organic Anion–Transporting Polypeptides , 2006 .

[144]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide , 2008, Journal of clinical pharmacology.

[145]  H. Kroemer,et al.  In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). , 2011, Handbook of experimental pharmacology.

[146]  R. Kim,et al.  Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) , 2011, Drug Metabolism and Disposition.

[147]  Mark N Milton,et al.  P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. , 2010, Drug metabolism letters.

[148]  S. Masuda,et al.  Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.

[149]  M. F. Kanz,et al.  Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road. , 2006, Pharmacology & therapeutics.

[150]  R. Kim,et al.  Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). , 2008, Drug metabolism reviews.

[151]  B. Stricker,et al.  Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response , 2010, Pharmacogenetics and genomics.

[152]  M. Hayden,et al.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.

[153]  Balram Chowbay,et al.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.

[154]  Hiroaki Yuasa,et al.  The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine , 2009, Drug Metabolism and Disposition.

[155]  B. Långström,et al.  Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.

[156]  Junjeong Choi,et al.  Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans , 2008, Clinical pharmacology and therapeutics.

[157]  H. Rosing,et al.  Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.

[158]  Yibo Wang,et al.  Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. , 2011, American journal of hypertension.

[159]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[160]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[161]  Wolfgang Löscher,et al.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.

[162]  K. Giacomini,et al.  Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.

[163]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[164]  A. Morris,et al.  Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.

[165]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[166]  M. Krajinovic,et al.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. , 2009, Blood.

[167]  Yusuke Nakamura,et al.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.

[168]  Adam L VanWert,et al.  Organic Anion Transporter 3 (Oat3/Slc22a8) Interacts with Carboxyfluoroquinolones, and Deletion Increases Systemic Exposure to Ciprofloxacin , 2008, Molecular Pharmacology.

[169]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[170]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[171]  C. Rudin,et al.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  Teruhiko Yoshida,et al.  Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients , 2010, Cancer Chemotherapy and Pharmacology.

[173]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[174]  P. Giral,et al.  Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. , 2008, Pharmacogenomics.

[175]  U. Hofmann,et al.  Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.

[176]  Jos H. Beijnen,et al.  Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein , 1997, Nature Medicine.

[177]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[178]  S. Cole,et al.  Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1) , 2005, Pharmacogenetics and genomics.

[179]  José Manuel Fernández-Real,et al.  OCT1 Expression in Adipocytes Could Contribute to Increased Metformin Action in Obese Subjects , 2010, Diabetes.

[180]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[181]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[182]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[183]  R. Kim,et al.  Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin , 2008, Molecular Pharmacology.

[184]  E. van de Steeg,et al.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.

[185]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[186]  S. D. de Morais,et al.  Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds , 2008, Drug Metabolism and Disposition.

[187]  G. Suarez-Kurtz,et al.  The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. , 2010, British journal of clinical pharmacology.

[188]  P. Neuvonen,et al.  Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.

[189]  M. Niemi,et al.  Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Aliskiren , 2010, Clinical pharmacology and therapeutics.

[190]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[191]  M. Kool,et al.  A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome , 1997, Hepatology.

[192]  H. Trautmann,et al.  Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia. , 2009, Blood.

[193]  L. Chinn,et al.  ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.